Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Arcturus Therapeutics” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 13
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 13 pipeline programs matching "Arcturus Therapeutics" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

13 results for “Arcturus Therapeutics” Back to intelligence hub

Search results

  1. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial
  2. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial
  3. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial
  4. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial
  5. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial
  6. ARCT-032

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials
  7. ARCT-032-02

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 other active

    1 trial
  8. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial
  9. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial
  10. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials
  11. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial
  12. ARCT-2138

    Arcturus Therapeutics Holdings

    Influenza, Human

    phase 1 mab completed

    1 trial
  13. ARCT-2304

    Arcturus Therapeutics Holdings

    Influenza, Human

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.